FY2017 EPS Estimates for Amedisys Inc Increased by Jefferies Group (AMED)
Amedisys Inc (NASDAQ:AMED) – Equities researchers at Jefferies Group lifted their FY2017 earnings per share (EPS) estimates for shares of Amedisys in a report issued on Wednesday. Jefferies Group analyst B. Tanquilut now expects that the health services provider will earn $2.20 per share for the year, up from their prior forecast of $2.05. Jefferies Group currently has a “Buy” rating and a $57.00 price objective on the stock. Jefferies Group also issued estimates for Amedisys’ FY2018 earnings at $2.45 EPS.
Amedisys (NASDAQ:AMED) last released its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. The firm had revenue of $378.80 million for the quarter, compared to analyst estimates of $380.80 million. Amedisys had a return on equity of 12.60% and a net margin of 3.16%. The company’s revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.42 EPS.
Several other research firms have also issued reports on AMED. Benchmark Co. restated a “hold” rating and issued a $57.00 price objective (up previously from $50.00) on shares of Amedisys in a research note on Wednesday, May 3rd. Zacks Investment Research lowered Amedisys from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. Royal Bank Of Canada restated a “hold” rating and issued a $56.00 price objective on shares of Amedisys in a research note on Monday, June 5th. Mizuho upgraded Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price objective on the stock in a research note on Wednesday, May 3rd. Finally, BidaskClub lowered Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 12th. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $56.50.
Amedisys (AMED) traded down 0.57% during mid-day trading on Friday, reaching $46.71. The company’s stock had a trading volume of 623,373 shares. The company has a 50 day moving average of $60.87 and a 200-day moving average of $54.00. Amedisys has a 52-week low of $34.58 and a 52-week high of $65.91. The stock has a market cap of $1.58 billion, a PE ratio of 34.60 and a beta of 0.94.
In other news, insider Scott G. Ginn sold 23,828 shares of the company’s stock in a transaction that occurred on Monday, May 8th. The stock was sold at an average price of $58.62, for a total value of $1,396,797.36. Following the transaction, the insider now owns 13,018 shares of the company’s stock, valued at $763,115.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jake L. Netterville sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. Following the completion of the transaction, the director now directly owns 77,499 shares in the company, valued at approximately $4,649,940. The disclosure for this sale can be found here. Insiders sold 56,828 shares of company stock worth $3,350,922 in the last ninety days. 2.80% of the stock is owned by company insiders.
Several institutional investors have recently bought and sold shares of AMED. Ameritas Investment Partners Inc. purchased a new position in Amedisys during the first quarter valued at approximately $123,000. State of Alaska Department of Revenue increased its stake in shares of Amedisys by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock worth $157,000 after buying an additional 70 shares in the last quarter. CIBC Asset Management Inc bought a new stake in shares of Amedisys during the second quarter worth about $230,000. Redmile Group LLC bought a new stake in shares of Amedisys during the first quarter worth about $247,000. Finally, Suntrust Banks Inc. increased its stake in shares of Amedisys by 2.0% in the first quarter. Suntrust Banks Inc. now owns 5,465 shares of the health services provider’s stock worth $279,000 after buying an additional 107 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.